Clinical Trials | September 11, 2024
Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
ALS patients experience neuroinflammation and rapid neurodegeneration
ALS patients experience neuroinflammation and rapid neurodegeneration
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Subscribe To Our Newsletter & Stay Updated
